Vnitr Lek 2010, 56(9):967-971

Serum lipoprotein profile in newly recognized arterial hypertension. The role of atherogenic lipoproteins in the pathogenesis of disease

S. Oravec*, A. Dukát, P. Gavorník, M. Čaprdna, M. Kučera
II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MUDr. Andrej Dukát, CSc., FESC

New examination approaches in biochemical analysis of lipoproteins can identify and quantify atherogenic plasma lipoproteins, including small dense LDL and characterise a lipoprotein spectrum as a non-atherogenic lipoprotein profile phenotype A, respectively as an atherogenic lipoprotein profile phenotype B. Identification of a non-aterogenic hypercholesterolemia (48%), atherogenic hypertriglyceridemia (93%), atherogenic normolipemia (13%) in patients with arterial hypertension and an atherogenic normolipemia in control group of healthy subjects (7%), is an essential contribution of this new laboratory diagnostics.

Keywords: atherogenic lipoprotein profile; non-atherogenic hypercholesterolemia; atherogenic normolipemia

Received: June 17, 2010; Published: September 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Oravec S, Dukát A, Gavorník P, Čaprdna M, Kučera M. Serum lipoprotein profile in newly recognized arterial hypertension. The role of atherogenic lipoproteins in the pathogenesis of disease. Vnitr Lek. 2010;56(9):967-971.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Felmeden DC, Spencer CG, Blann AD et al. Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. Hypertension 2003; 41: 528-533. Go to original source... Go to PubMed...
    2. Whitworth JA. World Health Organisation (WHO), International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertension 2003; 21: 1983-1992. Go to original source... Go to PubMed...
    3. Horký K. Systémová arteriální hypertenze. In: Klenner P et al (eds). Vnitřní lékařství. Praha: Galén 1998: 137-149.
    4. Rubies-Prat J, Ordónez-Llanos J, Martin S et al. Low-density lipoprotein particle size, triglyceride-rich lipoproteins and glucose tolerance in non-diabetic men with essential hypertension. Clin Exp Hypertens 2001; 23: 489-500. Go to original source... Go to PubMed...
    5. Landray MJ, Edmunds E, Li-Saw-Hee FL et al. Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension. QJM 2002; 95: 165-171. Go to original source... Go to PubMed...
    6. Zhao CX, Cui YH, Fan Q et al. Small dense low-density lipoproteins and associated risk factors in patients with stroke. Cerebrovasc Dis 2009; 27: 99-104. Go to original source... Go to PubMed...
    7. Austin MA. Triglyceride, small dense low-density lipoprotein and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200-207. Go to original source... Go to PubMed...
    8. Van J, Pan J, Charles MA et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679-1685. Go to original source...
    9. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395-403. Go to original source... Go to PubMed...
    10. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-1379. Go to original source... Go to PubMed...
    11. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069. Go to original source... Go to PubMed...
    12. Shoji T, Hatsuda S, Tsuchikura S et al. Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582-588. Go to original source... Go to PubMed...
    13. Hoefner DM, Hodel SD, O'Brien JF et al. Development of a rapid quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001; 472: 266-274. Go to original source...
    14. Oravec S. Nová laboratórno-medicínska pomoc v diagnostike dyslipoproteínemií a kardiovaskulárnych ochorení: Identifikácia LDL podskupín. Med Milit Slov 2006; 8: 28-32.
    15. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B. Go to original source... Go to PubMed...
    16. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86: 943-949. Go to original source... Go to PubMed...
    17. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069. Go to original source... Go to PubMed...
    18. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749. Go to original source... Go to PubMed...
    19. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A. Go to original source... Go to PubMed...
    20. Oravec S. Identifikácia subpopulácií LDL triedy - Aktuálny prínos v diagnostike porúch metabolizmu lipoproteínov a ochorení kardiovaskulárneho systému. Med Milit Slov 2006; 8: 32-34.
    21. Oravec S. Nové perspektívy v diagnostike porúch metabolizmu lipoproteínov - prínos v interpretácii výsledkov. Med Milit Slov 2007; 9: 42-45.
    22. Oravec S. Nové možnosti posúdenia kardiovaskulárneho rizika u pacientov s obezitou a metabolickými ochoreniami. Med Milit Slov 2007; 9: 46-49.
    23. Oravec S. Den drohenden Herztod erkennen - und vermeiden. Der Mediziner 2010; 4: 6-7.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.